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Abstract  
Portal hypertension is the main driver of cirrhosis decompensation, the main determinant of death 
in patients with cirrhosis. Portal hypertension results initially from increased intrahepatic vascular 
resistance. Later, increased inflow from splanchnic vasodilation and increased cardiac output lead to 
a further increase in portal pressure. Reducing portal pressure in cirrhosis results in better 
outcomes. Removing the cause of cirrhosis might improve portal pressure. However, this is a slow 
process and patients may continue to be at risk of decompensation. Additionally, for some chronic 
liver diseases, such as non-alcoholic fatty liver disease, etiological treatments are not yet available. 
Therefore, there is a need to develop better therapies specifically aimed at reducing portal pressure. 
For over 35 years, the mainstay of such therapy has been the use of nonselective beta-blockers that 
act by reducing portal venous inflow. Recently, many drugs (mainly targeting intrahepatic 
mechanisms) have shown promise in pre-clinical and early clinical studies and may act alone or 
synergistically with nonselective beta-blockers in reducing portal pressure in cirrhosis.  The objective 
of this position paper is to propose a novel framework for the design of clinical trials (phase 1, 2 and 
3) in patients with cirrhosis and portal hypertension and to prioritize novel targets and 
pharmacological therapies in this setting. We have focused the discussion on patients with 
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compensated cirrhosis. The paper summarizes discussions held at The American Association for the 
Study of Liver Diseases (AASLD) Industry Colloquium in January 2018, with the participation of 
clinical and translational investigators, regulatory professionals and industry partners. 
 
I. Introduction 
Portal hypertension (PH) is the main consequence of cirrhosis and is the main driver of cirrhosis 
decompensation (1).  Cirrhosis decompensation is defined by the presence of clinical complications 
(ascites, variceal hemorrhage, encephalopathy) and constitutes the main determinant of death in 
patients with cirrhosis (2).  
PH results initially from increased intrahepatic resistance due to architectural distorsion and 
intrahepatic vasoconstriction (3).  At this stage, PH is mild but leads to increase in vasodilators in the 
splanchnic vasculature that result in increased portal venous inflow.  This increased inflow leads to a 
further increase in portosystemic gradient and, once it surpasses a certain level (clinically significant 
portal hypertension), the patient becomes more susceptible to decompensation (4).  
Elimination of the underlying cause of cirrhosis may lead to a reduction in fibrosis and to an 
improvement in PH.  For example, elimination of the hepatitis C virus has been associated with a 
reduction in portal pressure in patients with cirrhosis (5, 6).  However, once PH becomes clinically 
significant, it is unlikely to regress, at least in the short term, and the patient continues to be at risk 
of decompensation (6, 7).  Additionally, there are etiologies (e.g. non-alcoholic fatty liver disease) for 
which etiological treatment is not yet available.   
Reducing portal pressure in cirrhosis, independent of elimination of the cause of liver damage, 
results in better outcomes (8, 9).  Therefore, there is still a need to develop therapies that reduce 
portal pressure by targeting its main pathogenic vascular mechanisms.  For over 35 years, the 
mainstay of such therapy has been the use of nonselective beta-blockers (NSBB) that act by reducing 
portal venous inflow.  
Recently, many drugs (mainly targeting intrahepatic mechanisms) have shown promise in pre-clinical 
and early clinical studies.  The American Association for the Study of Liver Diseases (AASLD), at its 
yearly Industry Colloquium (January 19-20,2018), invited members of the AASLD Portal Hypertension 
Special Interest Group (SIG) to participate in a symposium that had the objective of discussing novel 
therapies in PH from the perspective of clinical and translational investigators, with participation 
from regulatory professionals and industry partners. 
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The objective of this position paper, as discussed in the symposium, is to propose a novel framework 
for the design of clinical trials (phase 1, 2 and 3) in patients with cirrhosis and PH and to prioritize 
novel targets and pharmacological therapies for PH. 
 
II. Preclinical studies in portal hypertension 
The initial mechanism in the pathogenesis of PH, an increase in intrahepatic vascular resistance, is 
due to a combination of structural changes (i.e., fibrosis, disruption of sinusoidal structure, 
microthrombi) and increased sinusoidal resistance (i.e. vasoconstriction) that results from increased 
contraction of activated hepatic stellate cells in the setting of increased vasoconstrictors and to 
dysfunctional endothelial cells with decreased production of vasodilators such as nitric oxide (NO) 
(3).  In response to intrahepatic changes and/or mild increases in portal pressure, splanchnic and 
systemic vasodilation and angiogenesis follow, leading to increased portal venous inflow and 
worsening of PH (10, 11).   
The complexity of PH is evident by the divergent actions of vasoconstrictive and vasodilating systems 
in the intrahepatic vs. the extrahepatic circulations.  Vasoconstrictors such as angiotensin II and 
norepinephrine contribute to intrahepatic vasoconstriction (10).  Rho-kinase, a key pathway in the 
maintenance of basal vascular tone, is dysregulated in both the intrahepatic and the extrahepatic 
circulations; while in the liver it contributes to vasoconstriction, in the extrahepatic vessels 
contractility is almost completely lost leading to vasodilatation (10). Conversely, availability of the 
vasodilator NO is reduced in the liver and increased in the extrahepatic tissues (3).  Due to these and 
other changes, even the strongest vasoconstrictors like angiotensin II or epinephrine fail to constrict 
extrahepatic vessels, while the intrahepatic vascular bed shows exaggerated contraction.  Therefore, 
it becomes a major challenge to select systemic therapies for PH in cirrhosis because 
vasoconstrictors (that would target splanchnic vasodilatation) will worsen intrahepatic resistance 
and vasodilators (that would target intrahepatic vasoconstriction) will lead to systemic hypotension 
and its downstream deleterious consequences. 
Systemic and splanchnic vasodilatation is a key component of the hyperdynamic syndrome in 
cirrhosis and is characterized clinically by low blood pressure and increased cardiac output.  It not 
only leads to the development of clinically significant PH and portosystemic collaterals but is also 
responsible for sodium and water retention, all of which eventually lead to the development of 
clinical decompensation (12).  In a stage of further progression of liver disease, systemic hypotension 
develops mainly due to further vasodilatation and a relative decrease in cardiac output, leading to 
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refractory ascites and hepatorenal syndrome (13). Systemic hypotension on the one side and clinical 
immunological events (e.g. systemic inflammation, infections) on the other side lead to impaired 
organ perfusion and dysfunction, and the development of multiorgan failure in cirrhosis (the so-
called acute-on-chronic liver failure) (14).  Therefore, the selection of targets could be different in 
compensated and decompensated cirrhosis depending on the objective of treatment (Figure 1). 
Table 1 provides a list of drugs that, in pre-clinical studies, have been shown to reduce portal 
pressure, including their purported site of action and other potential benefits as well as potential 
deleterious effects.  Of them, only statins have gone on to proof-of-concept clinical trials leading to a 
randomized controlled trial (RCT) with clinical outcomes (15-17).  Statins, are approved drugs for the 
treatment of hypercholesterolemia but they are pleiotropic drugs that are also Rho-kinase inhibitors 
and have anti-fibrotic effects. The use of statins is an example of how drugs that are in clinical use 
for other indications can be repurposed for the treatment of PH and this constitutes a promising 
model. 
The complexity of the processes involved in PH and in the development of complications of cirrhosis 
would favor the pursuit of multi-targeted therapies such as statins or of combination therapies 
addressing different targets.  An attractive possibility is cell-specific targeting of important pathways.  
Further research and development is still needed but there are currently several avenues to pursue 
(table 1).  
 
III. Pharmacokinetic (PK) and pharmacodynamic (PD) evaluation in portal 
hypertension clinical trials (Phase 1 and Phase 2) 
PK studies are generally undertaken during Phase1b and/or Phase2a clinical trials. In addition to 
investigating PK in healthy volunteers, there should be close attention to understanding the 
compound’s pharmacokinetic characteristics in hepatically impaired populations. Several 
pathophysiological changes which regularly occur in individuals with cirrhosis and PH can 
significantly impact drug disposition in this population (Table 2) (18-23).  The 2003 Food and Drug 
Administration (FDA) Guidance for Industry (24)recommends a formal PK study in hepatically 
impaired individuals if (a) hepatic metabolism and/or excretion accounts for > 20% of the absorbed 
drug’s or its active metabolite’s disposition, or (b) if the test compound is either known or suspected 
to have a narrow therapeutic window, or (c) if there is insufficient information about the 
compound’s metabolism and excretion and its predicted therapeutic window.  However, a formal PK 
study in hepatically impaired may not be necessary if a compound is entirely renally excreted with 
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no involvement of the liver, or if a drug is gaseous or volatile and  its active metabolite(s) are 
primarily eliminated via the lungs (24).  
PK studies can have a basic full study design, a reduced study design, or a population PK approach. 
The basic full study design involves the entire Child-Pugh spectrum (at least 6 patients in each Child-
Pugh category) and controls, whereas a reduced study design allows for the study to be limited to 
eight patients with Child-Pugh B cirrhosis and eight controls matched by age, gender, and co-
morbidities. The findings from a reduced study design conducted on Child-Pugh B patients, while 
considered applicable to individuals with Child-Pugh A cirrhosis, would be generally contraindicated 
in Child-Pugh C patients.  Although widely employed, limiting PK studies to a reduced study design is 
not recommendable as individuals with Child-Pugh A (mostly compensated) and Child B (mostly 
decompensated) cirrhosis may have markedly different pathophysiological abnormalities (e.g., 
plasma protein binding, hepatic blood flow, or intrinsic clearance).  One might consider a staged 
approach to a basic full study design where individuals with Child-Pugh A and B are investigated 
initially, assuming that initial efficacy and safety studies are limited to patients with mild to 
moderate Child-Pugh cirrhosis.  Conducting PK studies in individuals with severe liver dysfunction is 
challenging due to their tenuous health status with frequent complications and hospitalizations and 
multiple concomitant medications.  Wherever possible, controls in these studies should not be 
healthy volunteers but should be matched for age, gender, co-morbidities and concomitant 
medications. A single-dose PK study might be sufficient if a compound and its metabolite exhibits 
linear and time-independent PK at concentrations anticipated in the patients to be studied and are 
not expected to change in patients with cirrhosis and PH. Although their validity is not fully 
established in patients with cirrhosis and PH, population pharmacokinetic analyses should be built 
into Phase3 and Phase4 studies wherever possible as such data can be quite instructive in fully 
understanding the PK characteristics.   
Patients with cirrhosis may respond differently than the general population to medications due to 
accompanying pathophysiological abnormalities. These include plasma protein binding, decreased 
skeletal muscle mass, alterations in blood brain barrier, reduced renal blood flow, and increased QT 
interval. Some examples of altered PD in cirrhosis include: unresponsiveness to loop diuretics in 
patients with refractory ascites (25), risk of acute kidney injury from non-steroidal anti-inflammatory 
drugs in patients with cirrhosis especially ascites (26), and more recent description of worsened 
insulin sensitivity from nadolol in patients with cirrhosis (27).  PD assessments should be considered 
on a compound by compound basis, especially if concentration-response relationship is unknown, or 
if altered hepatic function and/or PH are suspected to alter PD response. It is our understanding that 
the FDA is in the midst of revising its guidance for PK studies in hepatic impaired population.  It is 
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possible that MELD score (rather than Child-Pugh classes) forms the basis for future PK studies in 
patients with cirrhosis.  
 
Safety Monitoring in Cirrhosis and Portal Hypertension Clinical Trials 
Monitoring for hepatic and extrahepatic toxicity is very important in drug development for cirrhosis 
and PH.  Two important considerations in monitoring for hepatotoxicity are (a) challenges in 
biochemical monitoring as baseline aminotransferases and bilirubin may be abnormal and (b) due to 
lower functional hepatic reserve, patients may be at risk for rapid decompensation and death, even 
with injuries that are otherwise not as serious (for example, cholestatic liver injury) (28).  Patients 
with cirrhosis may be at risk for extrahepatic (off target)  adverse events due to systemic 
pathological changes such as decreased plasma protein, altered volume of distribution, decreased 
skeletal muscle mass, decreased renal blood flow, and increased blood brain permeability, and 
altered gut permeability.  Further, these patients may already be taking other medications and thus 
may be exposed to drug-drug interactions.  Every study should have a well thought out plan for 
safety monitoring and stopping rules and the data safety and monitoring boards should include 
hepatologists with familiarity in drug safety and causality adjudication. 
 
IV. Proof-of-concept studies (phase 2) trials in portal hypertension 
a) Selection of relevant population 
Cirrhosis is subclassified in two main clinical stages, compensated and decompensated, each of them 
with different prognosis and different predominant pathogenic mechanisms and therefore different 
therapeutic targets (29). Patients with compensated and decompensated cirrhosis should be 
investigated or analyzed separately in clinical trials. 
Compensated cirrhosis is the asymptomatic and the longest stage of cirrhosis.  In this stage, the 
patient with chronic liver disease and/or chronic risk factors for liver disease (e.g. alcohol ingestion, 
HCV infection) has histological, imaging or elastographic evidence of cirrhosis but has not developed 
any decompensating events (ascites, variceal hemorrhage or encephalopathy). Median survival is 
around 15 years (30).   
Compensated cirrhosis is sub-classified by the severity of PH into those with mild portal 
hypertension (MPH) and those with “clinically significant” portal hypertension (CSPH).  These two 
stages are different not only in the degree of PH but also regarding their risk of progression to 
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decompensation, the amount of hepatic fibrosis and the predominant pathogenic mechanisms.  
While patients with MPH have a very low risk of decompensation, have less liver fibrosis (and 
thinner fibrous septa) and the main pathogenic mechanism is increased intrahepatic resistance, 
those with CSPH have a 4-times higher risk of decompensation than patients with mild PH (1), have 
more liver fibrous tissue (31) and, in addition to intrahepatic resistance, a main contributor to PH is 
increased splanchnic blood flow (4). Because non-selective beta-blockers (NSBB) act by decreasing 
flow, the portal pressure response to NSBB is much lower in patients with MPH compared to those 
with CSPH (4).  
Treatment of underlying disease, if possible, is the most effective and appropriate treatment at the 
compensated stage.  In patients with mild PH, it is conceivable that this treatment (or antifibrotic 
treatment when available) could lead to regression to a non-cirrhotic stage or at least to halting the 
progression to CSPH.  However, although treatment of the primary liver disease may slow 
progression to decompensation in patients with CSPH, the risk is not eliminated and a substantial 
number of patients remain with CSPH and at risk for decompensation.  It is in these patients and in 
those for whom specific etiologic therapies are unavailable where measures to reduce portal 
pressure will be more important. 
Decompensated cirrhosis is the symptomatic and shorter stage of cirrhosis.  This stage is 
characterized by the presence of clinical complications, specifically ascites, variceal hemorrhage, 
encephalopathy and jaundice (although the latter is very rare as first decompensating event) (29). 
Median survival is 1.5 years (30).  The type and number of decompensating events is of prognostic 
importance as is the presence of further complications of decompensating events such as 
hepatorenal syndrome (“further” decompensation”). Decompensated patients have, by definition, 
CSPH.  Although worsening vasodilatation and inflammation contribute to outcomes in these 
patients, PH still plays a major role as outcomes improve with reduction in portal pressure (8, 32). 
 
b) Measurement of portal pressure and definition of mild vs. CSPH 
The hepatic venous pressure gradient (HVPG) is the main method used to measure portal pressure.  
It consists of the percutaneous catheterization of a hepatic vein (mostly via the transjugular route) 
with measurements of the wedged hepatic vein pressure (WHVP) and the free hepatic vein pressure 
(FHVP) (33).  The WHVP is obtained by either advancing the catheter until it is wedged in the most 
distal portion of the hepatic vein or, preferably, by inflating a balloon at the end of a catheter in a 
more proximal portion of the vein.  It is a measure of hepatic sinusoidal pressure and correlates 
closely with portal pressure in viral, alcoholic and non-alcoholic steatohepatitis cirrhosis where there 
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is sinusoidal and/or post-sinusoidal fibrosis. The FHVP is a measure of systemic pressure and is used 
as an internal zero to “correct” the WHVP.  The HVPG is therefore obtained by subtracting the FHVP 
from the WHVP.  Normal HVPG is 3-5 mmHg.  An HVPG > 5 mmHg indicates the presence of PH and 
an HVPG ≥10 mmHg indicates the presence of CSPH. 
Although all patients with cirrhosis should theoretically have an abnormal portal pressure (i.e. HVPG 
> 5 mmHg), the HVPG is normal in ~10% of patients with histological/clinical cirrhosis.  This could be 
due to sampling error in the biopsy, a predominantly presinusoidal fibrotic component, or to an 
inadequate occlusion of the hepatic vein due to the presence of intrahepatic shunts. 
Sub-classification of patients into mild vs. CSPH is based on the HVPG. Mild PH is defined as an HVPG 
>5 mmHg but less than 10 mmHg.  CSPH is defined as an HVPG ≥ 10 mmHg.  Because patients with 
varices and/or decompensation have an HVPG of at least 10-12 mmHg, patients with varices (or 
collaterals on imaging) and/or clinical decompensation by definition have CSPH (12). 
Non-invasive approaches to assess the presence of CSPH include measurements of liver stiffness 
with or without additional parameters such as platelet count and/or spleen size (34).  The presence 
of varices that have not bled or a history of variceal hemorrhage can be used to select candidates for 
studies of patients with CSPH.  However, standard of care would require that some of these patients 
(those with moderate/large varices) receive therapies to prevent variceal hemorrhage (either NSBB 
and/or ligation) that could confound the interpretation of results.  If included in a single study, 
patients with compensated and decompensated cirrhosis would require separate analysis. 
 
c) Definition of HVPG response 
Drugs identified in pre-clinical studies with a portal pressure-reducing effect (candidate drugs) 
should be tested on their ability to reduce HVPG in patients with CSPH.  Unfortunately, until now, 
there is not a single non-invasive test (e.g. Doppler, liver stiffness) whose changes correlate with 
changes in HVPG and that would be acceptable alternatives to paired HVPG measurements. 
The magnitude of change in the HVPG required to predict that a drug has potential clinical utility in 
patients with CSPH is still controversial.  In patients with a history of variceal hemorrhage, a 
decrease in HVPG to less than 12 mmHg or a decrease greater than 20% from baseline is associated 
with a significant reduction in the risk of recurrent hemorrhage, ascites, encephalopathy and death 
(8).   Reductions in HVPG >10% from baseline have been associated with a reduction in variceal 
development (35), first variceal hemorrhage and death (9).   
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It is important to note that these threshold HVPG reductions apply to NSBB-based therapies, which 
act by decreasing portal blood inflow and may not apply to drugs that decrease intrahepatic 
resistance which, while decreasing portal pressure only modestly may have a mild effect in 
preventing bleeding, but by improving liver perfusion may have a more important effect on survival 
(16, 17) 
Importantly, using the most common cutoffs (reduction of HVPG to <12 mmHg or >20% 
from baseline) to classify patients in a dichotomous fashion into HVPG “responders” and 
“non-responders” may underestimate the value of a candidate drug.  While “responders” 
have in fact been shown to have better clinical outcomes than non-responders, the 
definition lacks sensitivity as many patients not meeting these criteria may still have a good 
clinical response to therapy (36).  It would be unwise to rule out a potential therapeutic 
benefit for a drug that achieves a consistent decrease in portal pressure, even if this 
decrease in portal pressure does not reach the threshold used to define a good response.  
On the other hand, preliminary analyses of a dynamic HVPG model obtained from patients 
with compensated cirrhosis without varices included in the timolol study, demonstrates 
that, at any time during follow-up, a 1 mmHg increase (or decrease) in HVPG is associated 
with a 1.19-times higher (or lower) risk of decompensation/death (95%CI:1.11-1.27) (37).  
This model provides much more granularity to changes in HVPG and, if confirmed, a proof-
of-concept study could be powered on a pre-defined specific reduction in HVPG associated 
with a certain percentage reduction in decompensation in the patient population to be 
analyzed.  Furthermore, if the proof-of concept study includes clinical outcomes, results 
could inform a potential effect size for a phase 3 trial. 
 
d) Comparator to be used 
In proof-of-concept studies that investigate the effect of a candidate drug on HVPG, the use of a 
placebo of the candidate drug(s) is mandatory. 
If the investigational drug has a different mechanism of action from the standard of care (NSBB in 
patients with medium/large varices), patients on these drugs should be stratified separately to 
investigate the presence of a synergistic or additive effect of the candidate drug. 
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e) Readouts other than HVPG to be investigated in proof-of-concept (POC) studies 
(Table 3) 
Candidate drugs with a purported intrahepatic mechanism of action (i.e. reduction of intrahepatic 
resistance) may have a more important effect by improving liver perfusion while demonstrating an 
only modest effect on portal pressure.  Therefore, analysis of these drugs should include 
quantitative tests of liver perfusion such as the indocyanine green clearance test, or breath tests 
that analyze clearance of ingested or injected markers.   
Other readouts that should be prospectively collected are the development of clinical outcomes 
during the course of the study (clinically overt decompensating events) as well as potentially 
negative readouts such as reduction in mean arterial pressure or cardiac output or development of 
renal dysfunction, and other adverse events.  
In addition, analyses that would support the purported mechanism of action of the candidate drug 
would be desirable as a correlation between the hemodynamic effect and mechanistic markers 
would support advancing to a phase 3 trial. These analyses may disclose useful biomarkers of the 
response to this specific drug.  
As in any clinical trial evidence of hepatotoxicity or other adverse events should be collected in the 
knowledge that the study population (compensated cirrhosis) may have low tolerance to even mild 
adverse events. 
 
f) Other considerations 
- Duration of therapy:  Depends on the proposed mechanism of action of the 
candidate drug.  If it has direct vasoactive action, the HVPG response could be 
assessed acutely after a short period as has been demonstrated after the 
intravenous administration of propranolol (9).  However, it would be necessary to 
continue the drug and have a follow-up HVPG after longer administration to 
demonstrate that the effect is maintained and is not offset by compensatory 
mechanisms (as occurs with long-acting nitrates).  Drugs targeting the structural 
component of the increased hepatic resistance (e.g. antifibrotic drugs) may take 
much longer (e.g., 12 months) to demonstrate HVPG reductions.  
- Confounders such as concomitant treatment of underlying cause of liver disease (e.g. 
weight loss, antiviral therapy), co-morbidities (e.g. alcohol use, cardiovascular 
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disease) or treatment of co-morbidities that may affect HVPG (e.g. statins, 
vasoactive medications) should be considered.  
In summary, POC studies in PH should include patients with cirrhosis and CSPH, with the main 
readout being a decrease in HVPG.  Other readouts (positive and negative) and findings should 
inform the decision to move on to phase 3 trials. 
 
V. Phase 3 trials in portal hypertension 
Most clinical trials in PH have been directed towards treating or preventing variceal hemorrhage. 
However, varices and variceal hemorrhage are not isolated events and they must be considered in 
the context of the presence (or absence) of other decompensating events (2, 12). Therefore, the aim 
of clinical trials in PH should be to prevent, not only variceal hemorrhage, but any form of 
decompensation. Unfortunately, a paucity of data currently exists in this area, and RCTs are needed. 
Trial design in patients with decompensated cirrhosis has been extensively discussed elsewhere (2) 
and we therefore focus the discussion on patients with compensated cirrhosis. 
 
a) Primary endpoint 
In agreement with the consensus achieved at the 2015 Baveno workshop on PH (2), the 
development of a decompensating event (ascites, variceal hemorrhage and/or encephalopathy) 
should be the main primary endpoint in Phase 3 trials.  Such composite endpoint provides certain 
advantages.  Most importantly, the combination of clinical variables provides the most clinically 
relevant measure of clinical well-being.  Additionally, in RCTS, a composite endpoint will enhance the 
ability to detect differences in outcomes.  It should be noted that ascites is the most common first 
decompensating event (followed by variceal hemorrhage and encephalopathy (38)). An objective 
and standardized definition of all these events is needed to adequately assess the main endpoint. 
Ascites, or free fluid in the peritoneal cavity, should be documented by imaging techniques and 
confirmed by diagnostic paracentesis (which is otherwise indicated in patients first presenting with 
ascites), as clinical signs of ascites are not accurate (39) .  Variceal hemorrhage should follow the 
definitions of the Baveno VI consensus conference (2). “Covert” hepatic encephalopathy is difficult 
to detect outside of specialized dedicated units, and reproducibility of this diagnosis is low (40). 
Therefore, encephalopathy should be “overt” (at a minimum confusion and asterixis, or West Haven 
Grade ≥2) and documented by a physician to be considered an endpoint. Many patients with 
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compensated cirrhosis are taking sedatives, anxiolytics or antidepressant drugs that may interfere 
with the recognition of mild encephalopathy. 
 
b) Development of varices as a part of the main primary endpoint  
Although the development of varices without decompensation is a sign of disease progression, this 
clinical feature should not be included as part of the primary endpoint.  Even though the 2-year risk 
of decompensation in patients with and without varices is different (~15% vs. ~8%, respectively) (1, 
30, 38, 41), there are several operational reasons for not considering varices as part of the primary 
endpoint. First, the trial would be limited to patients without varices, which have a much lower risk 
of decompensation than patients with varices. Second, the inter-observer agreement for small 
varices is low (42). Third, if development of varices is a component of a composite primary endpoint, 
development of varices would lead to the discontinuation of the study drug. This could result in 
missed opportunities when evaluating the efficacy of drugs that might prevent decompensation, but 
not the development of varices. In fact, in the study comparing tImolol or placebo for the prevention 
of varices (35), the development of varices led to drug discontinuation, precluding assessment of a 
potential effect on the development of ascites or other decompensating events. Very recent data, 
presented in abstract form, suggests that NSBB might have a strong effect preventing ascites in 
patients with cirrhosis and CSPH (43). 
The development of varices should be assessed as a secondary endpoint, but should not be part of 
the primary endpoint and should not lead to study drug discontinuation. This secondary endpoint 
could be analyzed as an exploratory ordinal outcome (considering death as the worst potential 
outcome, followed by decompensation and varices (Fig 2). Patients with varices fulfilling current 
recommendations for treatment either at baseline or during the trial should receive standard 
therapy to prevent first variceal hemorrhage, which in the context of a phase 3 drug therapy-based 
trial should preferably be endoscopic therapy. Ideally this should be standardized across centres. 
 
c) Use of a surrogate endpoint 
Using an outcome surrogate is attractive for studies where a low event rate is expected within the 
study timeframe.  A surrogate would not only reduce sample size and study duration but could also 
be considered appealing because it would be a substitute for a more severe clinical outcome.  
Because patients with compensated cirrhosis have an overall low rate of decompensation (30, 38), it 
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has been suggested that changes in HVPG could be used as a surrogate endpoint to support the 
approval of new treatments for PH (within the FDA accelerated approval framework) (44)). 
Although, as mentioned previously, demonstrating a decrease in HVPG is the main goal of phase II 
trials, several issues would need to be resolved before a drug could be approved based on HVPG 
response. First, the magnitude of HVPG response considered clinically relevant remains to be 
determined. Second, most of the data demonstrating an association between an HVPG decrease and 
a reduction in clinical outcomes were obtained in studies using NSBB (8), drugs that decrease portal 
pressure by decreasing portal blood inflow, or in studies using treatments for etiology, such as 
alcohol abstinence and antivirals (6, 7, 45). New drugs with different mechanisms of action (i.e, 
acting by decreasing hepatic resistance) would certainly decrease HVPG, but the association 
between the change in HVPG and clinical benefit might be different and require validation. This 
validation could be achieved by incorporating HVPG measurements in phase 3 trials (of drugs other 
than NSBBs) with clinical endpoints.  Thus, if the beneficial effect of a reduction in HVPG was to be 
validated in a phase 3 trial (i.e. correlated with an improvement in clinical outcome), this would 
strongly favor the approval of new therapies for PH purely based on their ability to reduce portal 
pressure, as is the case for therapies for arterial hypertension.   
 
d) Feasibility of RCTs with clinical endpoints in patients with compensated cirrhosis. 
The relevance of patient selection 
The target population to evaluate drugs that would prevent decompensation is that of patients with 
cirrhosis and CSPH. However, among these patients the risk of decompensation varies widely. 
Indeed, data from the cohort included in the timolol trial showed that for every mmHg increase in 
baseline HVPG there was a 13% increase in the risk of decompensation (figure 3) (1). This indicates 
that setting the threshold HVPG for inclusion in the study at a level above that defining CSPH (10 
mmHg), for example at 14 mmHg, would result in a higher rate of events in a shorter time period 
and a lower required sample size. Selecting patients based on HVPG would be feasible, as shown by 
recent studies (43), but may prove difficult in large phase 3 trials.  Examples of potential sample sizes 
according to the minimum expected effect size, length of follow-up and predicted rates of 
decompensation in the control group are provided in table 4. 
There are several non-invasive tools that could substitute for HVPG in its prediction of clinical 
outcomes in patients with compensated cirrhosis, including laboratory values and imaging-based 
techniques such as transient elastography. Unfortunately, these have not yet been well validated 
and will likely need to be disease specific since the association between these non-invasive tests and 
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the risk of decompensation might be quantitatively different among patients with viral, alcoholic and 
non-alcoholic fatty liver disease. 
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Table 1. Selected new candidate drugs with a proven effect in reducing portal pressure in pre-clinical studies and in some clinical studies. 
 
Drugs 
Pre-clinical studies Proof of concept studies 
Phase 3 
trials 
Purported site of action 
(intrahepatic, extrahepatic 
or both) 
Effect other than  in PP 
Potential 
deleterious 
signal 
Reduced HVPG 
Positive effect 
other than on 
HVPG 
AEs observed 
 
Statins Intrahepatic (10, 24, 46) Antifibrotic (47) 
Rhabdomyolysi
s (24) 
Yes (16, 48, 49)  
Increased in 
Indocyanine geen 
clearance (16) 
Rhabdomyolysis, 
liver toxicity (17) 
Yes 
(decrease 
mortality) 
(17) 
PDE5-
inhibitors 
Intrahepatic  
(50-52) 
Antifibrotic (52) -  
+/- (discordant) 
(53-57) 
erectile 
dysfunction 
Hypotension No 
Sorafenib 
(anti-VEGF) 
Both 
(58-60) 
Antifibrotic, antiangiogenic 
(59) 
Hepatic injury 
(61) 
+/- (discordant) 
(62-64) 
Improved MAP Multiple No 
Poorly 
absorbed 
antibiotics 
(Rifaximin, 
Norfloxacin) 
Extrahepatic (65) 
Decreased bacterial 
translocation (65) 
-  
+/- (discordant) 
(66-70) 
Less HE, less 
decompensation 
(66, 67) 
- No? 
Caspase 
inhibitors 
Both (71, 72) Liver injury, fibrosis (71) -  Yes (73) 
Decrease AST 
(74) 
- No 
FXR-
agonists 
Both  
(75-77) 
Antifibrotic, decreased 
bacterial translocation (78-
81) 
- Yes (82)  - No  
Serelaxin  Intrahepatic (83) 
Improved Renal perfusion 
(84) 
-  No data (84) 
Improved Renal 
perfusion (84) 
-  No 
Enoxaparin Both (85, 86) Antifibrotic (85) -  
Ongoing trial 
(NCT02643212) 
 
Decreased 
decompensation, 
less portal vein 
-   
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Additional references (from #46 on) are provided as supplementary data 
 
 
 
 
 
thrombosis (87)  
Endothelin-
A receptor 
antagonists 
Intrahepatic (88) (89) 
 
 
Antifibrotic (89)  
Antiangiogenic (90)  
 
-  
+/- (discordant) 
(91, 92)  
 
-decreased 
pulmonary 
arterial pressure 
(treatment of 
portopulmonary 
hypertension) 
(91) 
-decreased mean 
arterial pressure 
(91) 
No 
Thalidomide Intrahepatic (93, 94)   
Antifibrotic, antiangiogenic, 
reduced systemic 
inflammation (93, 94)   
-  
Yes 
(95) 
 
 
Reduced 
systemic 
inflammation 
(95) 
- - 
Angiotensin 
II Type 1 
receptor 
blocker 
Intrahepatic  
(96-98) 
 
Antifibrotic (98), Improved 
renal perfusion as low dose 
(99) 
Arterial 
hypotension 
(96) 
+/- (discordant) 
(100-106) 
Antifibrotic (100)  
Arterial 
hypotension, 
Renal dysfunction 
(105, 106) 
 
No 
Taurine  
Intrahepatic and 
extrahepatic (107)  
Antifibrotic (107) - Yes (108) - - - 
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Table 2:  Mechanisms behind altered pharmacokinetics in patients with cirrhosis and portal 
hypertension 
 
 Mechanism Comments 
1 Reduced Intrinsic Capacity 
- Decreased enzyme levels 
- Decreased activity 
Liver disease etiology specific variability 
in different CYPs may exist - for example, 
alcohol and infection can affect some 
CYPs selectively 
2 Reduction in blood flow  May affect drug disposition through a 
number of mechanisms.  
3 Shunts Intrahepatic shunts - may account for up 
to 65% of hepatic blood flow 
Spontaneous portosystemic shunts and 
TIPS can significantly modify 
4 Changes in protein binding Impacts delivery of drugs to hepatocytes 
and can also have an impact on 
pharmacodynamic response 
5 Reduced delivery of oxygen Oxygen is important for CYP activity 
6 Altered transporter expression and function Hepatocyte uptake as well as efflux into 
biliary canaliculi can be affected 
7 Small bowel CYP activity TIPS significantly reduces small bowel 
CYP3A activity 
8 Drug-drug interactions Altered pharmacokinetics of one 
compound may have secondary effects 
on the pharmacokinetics of co-
adminstered drugs 
9 Impaired renal function Pharmacokinetics of renally excreted 
drugs may be profoundly affected in 
individuals with cirrhosis 
10 Altered intestinal absorption There may be diminished absorption of 
orally administered drugs and may also 
influence the pharmacokinetics of drugs 
which are bile excreted due to impaired 
enterohepatic circulation 
 
Abbreviations:  CYP: Cytochrome P450; TIPS: Transjugular intrahepatic portosystemic shunts 
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Table 3.  Readouts (positive or negative) to be evaluated in proof-of-concept studies of candidate 
drugs for portal hypertension. 
 
Positive readouts Negative readouts 
 Decrease in HVPG  Decrease in mean arterial pressure / 
renal perfusion 
 Improvement in liver perfusion/liver 
synthetic function (breath tests, ICG, 
Hepquant) 
 Decrease in liver perfusion/liver 
synthetic function (breath tests, ICG) 
 Tendency for improvement in clinical 
outcomes (including mortality)  Evidence of hepatotoxicity 
 Results support a mechanism of action  Drug interactions 
 Definition of determinants of 
response 
 Other adverse events (low tolerance) 
 Improvement in patient reported 
outcomes 
 Applicability 
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Table 4: Examples of approximate sample sizes that would be needed in trials for the prevention of 
decompensation, according to the minimum effect size (which determines the number of events 
needed), and the rate of decompensation and length of follow-up (which determines the total 
sample size needed to achieve that number of events). Calculations were performed as proposed by 
Schoenfeld (Biometrics 1983;39:499-503) 
Minimum effect 
size (HR) 
N of events 
needed 
Median follow-up 
(yrs) 
Rate 
decompensation per 
year in the control 
group 
Total sample 
size 
0.7 247 1 15% ~1500 
0.7 247 2 15% 1000 
0.7 247 2 20% ~700 
      
0.6 120 1 15% ~1000 
0.6 120 2 15% ~500 
0.6 120 2 20% ~380 
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Figure legends: 
Fig 1: Different approaches to treat portal hypertension in cirrhosis.  Strategies to decrease portal 
pressure include drugs that act on intrahepatic targets: fibrosis, endothelial dysfunction, 
inflammation and drugs that act on decreasing portal flow: splanchnic vasculature, microbiome, and 
others such as the nervous system, fat, etc as recently reviewed (109,110).  A single drug may be able 
to affect more than one target (multitargeted approach): either two or more intrahepatic targets 
(e.g. statins) or one intrahepatic and one extrahepatic target (e.g. carvedilol).  If a multitargeted 
drugs is associated with unfavorable effects, the selective delivery either to the intrahepatic or to the 
extrahepatic circulation may be preferable.  Drug therapy should also be tailored to the stage of 
cirrhosis.  In compensated cirrhosis, the main treatment should target the underlying cause of 
cirrhosis in order to prevent progression of disease (or even to induce regression). Additionally, 
antifibrotic strategies together with drugs to decrease portal pressure (if significant portal 
hypertension is present) are beneficial in compensated cirrhosis, since fibrosis and portal 
hypertension are also self-maintaining processes. In decompensated cirrhosis (ascites, variceal 
hemorrhage), the main and short-mid-term goal should be reduction in portal pressure and 
prevention of further complications, since antifibrotic and etiological therapies, although also 
important, might not have the necessary short-term impact.  HSC=hepatic stellate cells;  IC= 
inflammatory cells; KC=Kupffer cells; SEC=sinusoidal endothelial cells. 
 
Fig 2: Example of a potential exploratory ordinal outcome including the development of varices. 
The development of varices would be hierarchically the less severe endpoint, followed by a first 
decompensation with only one event, and a first decompensation with more than one simultaneous 
decompensating event (i.e. variceal hemorrhage plus ascites or plus encephalopathy), which is 
associated with a much higher risk of death than a single decompensating event (41). Death (without 
decompensation) would be the most severe outcome. The analysis would test whether the study drug 
induces a significant “category shift” as compared to the control arm. 
Fig 3: Nomogram showing the 1,2 and 3 yr decompensation risk according to baseline HVPG 
(constructed with data published in Ripoll et al (1); details are provided in Supplementary File 1). 
Note the very different incidence of decompensation over time with increasing baseline HVPG values. 
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